[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576271":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":50,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":10,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Santa Chiara Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"mCRPC treated with olaparib",null,"mCRPC patients who receive olaparib in daily clinical practice",[13],"Drug: Olaparib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Olaparib","Olaparib given according the clinical practice to BRCA positive mCRPC patients",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Orazio Caffo, MD","CONTACT","+390461902478","orazio.caffo@apss.tn.it",[27,40],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Sabrina Rossetti","RECRUITING","Naples","Italy",{"type":33,"coordinates":34},"Point",[35,36],14.26811,40.85216,{"lat":36,"lon":35},[39],{"name":28,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":41,"status":29,"city":42,"state":10,"zip":10,"country":31,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Orazio Caffo","Trento",{"type":33,"coordinates":44},[45,46],11.12108,46.06787,{"lat":46,"lon":45},[49],{"name":41,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":51,"investigatorFullName":41,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","MD","100576271",false,"NCT06783127","Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer","Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study","COROS","Inclusion Criteria:\n\nBRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice\n\nExclusion Criteria:\n\nOlaparib treatment in a clinical trial","MALE",{"count":62,"type":63},3000,"ESTIMATED","OBSERVATIONAL","This is an observational, retrospective\u002Fprospective, multicenter study designed to define, overall survival, clinical outcomes and predictive\u002Fprognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.",[67,68,69],"Prostate Cancer","Castrate Resistant Prostate Cancer","BRCA Mutation","2025-02-07",{"date":72,"type":73},"2025-02-11","ACTUAL",{"date":75,"type":73},"2023-01-01",{"date":77,"type":63},"2026-12-31",{"name":5,"class":6},2]